Outcome and prognostic factors in 110 consecutive patients with primary uterine leiomyosarcoma: A Rare Cancer Network study
Authors:
- 1011 Lausanne Centre Hospitalier Universitaire Vaudois (Chuv)1(1011 Lausanne Centre Hospitalier Universitaire Vaudois (Chuv)
- Berardino De BariBBBerardino De Bari
- 1 January 2017
- journal article
- Published by Chinese Journal of Cancer Research in Chinese Journal of Cancer Research
- Vol. 29 (6) , 521-532
Abstract
Primary uterine leiomyosarcomas (ULMS) are rare, and the optimal treatment is controversial. We aimed to assess the outcome and prognostic factors in a multicenter population of women treated for primary ULMS. We retrospectively collected data of 110 women treated in 19 institutions of the Rare Cancer Network (RCN). Inclusion criteria consisted of a pathology report confirming the diagnosis of ULMS, aged 18-80 years, complete International Federation of Gynecology and Obstetrics (FIGO) stage information, complete information on treatment, and a minimum follow-up of 6 months. Local control (LC) and locoregional control (LRC), overall survival (OS) and disease-free survival (DFS) rates were computed using the Kaplan-Meier method. Univariate analysis was implemented using the log rank test, and multivariate analysis using the Cox model. All patients underwent surgery. Seventy-five patients (68%) received adjuvant radiotherapy (RT), including brachytherapy in 18 (16%). Seventeen patients (15%) received adjuvant chemotherapy. Median follow-up was 58 (range, 6-240) months. Five-year OS and DFS rates were 50% and 34%, and LC and LRC rates were 88% and 72%, respectively. On multivariate analysis, independent favorable prognostic factors were younger age, FIGO stage I, small tumor size, previous uterine disease, and no vascular invasion for OS and DFS. FIGO stage was the only favorable factor influencing LRC. Adjuvant local or systemic treatments did not improve the outcomes. Eight patients treated with RT presented a grade 3 acute toxicity, and only one patient with grade 3 late toxicity. In this large population of primary ULMS patients, we found good results in terms of LC and LRC. Nevertheless, OS remains poor, mainly due to the occurrence of distant metastases. An early diagnosis seemed to improve the prognosis of the patients. Adjuvant local or systemic treatments, or more aggressive surgical procedures such as the Wertheim procedure, did not seem to impact the outcome.Keywords
This publication has 37 references indexed in Scilit:
- Clinical Characteristics and Prognosis of Unexpected Uterine Sarcoma After Hysterectomy for Presumed Myoma With and Without Transvaginal Scalpel MorcellationInternational Journal of Gynecological Cancer, 2016
- The role of adjuvant therapy in uterine leiomyosarcomaExpert Review of Anticancer Therapy, 2015
- Postoperative radiotherapy in the treatment of uterine sarcomas: long-term results and analysis of prognostic factors.2010
- The Role of Adjuvant Radiation in Uterine SarcomasInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Pelvic Radiation Improves Local Control After Hysterectomy for Uterine LeiomyosarcomaInternational Journal of Gynecological Cancer, 2009
- Prognostic factors and survival in 1396 patients with uterine leiomyosarcomasCancer, 2008
- Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy☆Gynecologic Oncology, 2003
- A note on quantifying follow-up in studies of failure timeControlled Clinical Trials, 1996
- Prognostic factors in early‐stage uterine sarcoma: A gynecologic oncology group studyCancer, 1993
- A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.Journal of Clinical Oncology, 1985